GPs advised of extension to ADHD medication shortage

The Therapeutic Goods Administration (TGA) has informed GPs that the current shortage of Concerta modified-release tablets to treat attention deficit hyperactivity disorder (ADHD) will extend until the end of 2026.
 
This means there will continue to be periods when supply is limited or when some strengths are unavailable, the TGA said.
 
‘Methylphenidate products will continue to be available during the shortage but there will be periods when the supply is limited and some products are unavailable,’ the TGA advised.
 
‘Your patients may want to discuss ongoing treatment options while methylphenidate products are in shortage.’
 
The TGA is aiming to reduce the impact on patients by working with wholesalers to ensure fair distribution of existing stock and pharmaceutical companies.
 
It is also working alongside medical colleges and health bodies to develop clinical management advice about alternatives during the shortage.
 
Prescribers can be kept informed with the latest information on the Federal Government’s website as well as the Medicine Shortage Reports Database, where 368 medicines are currently in shortage.
 
The extended shortage comes as several states make moves to allow GPs to play a greater role in diagnosing and treating ADHD.
 
The New South Wales Government recently announced GPs will be able to resupply medication to patients with ADHD from September – the start of a rollout of ‘landmark reforms’ which will eventually allow GPs to diagnose the condition and initiate medication.
 
Several other states, including Western Australia and South Australia, are also introducing ADHD treatment reforms.
 
Log in below to join the conversation.

ADHD ADHD diagnosis ADHD treatment